Evaluation of adaptive immune cell profiles in the setting of combined TMZ and anti-CD47 treatment demonstrated a significant increase in both CD4+ and CD8+ T cells within the tumor (Fig. 5e). This evidence concerns the gene CD47 and neoplasm.